Cost effective short term G-CSF treatment in 2-weekly CHOP regimens for patients with aggressive NHL.

被引：0
|
作者：
Mantovani, L
Liebmann, A
Engel, C
Lehmann, T
Niederwieser, D
Loeffler, M
机构：
[1] Inst Med Stat & Epidemiol, Leipzig, Germany
[2] Clin 2 Internal Med, Leipzig, Germany
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3752
引用
收藏
页码：178B / 178B
页数：1
相关论文
共 50 条
  • [1] Rituximab-CHOP or 2-weekly CHOP plus G-CSF in aggressive lymphoma of the elderly?
    Bernardi, D
    Giacalone, A
    Spina, M
    Tirelli, U
    ANNALS OF ONCOLOGY, 2004, 15 (08) : 1298 - 1298
  • [2] Model based optimization of G-CSF scheduling in intensified CHOP-chemotherapies for NHL.
    Engel, C
    Stumpp, P
    Franke, H
    Schmitz, S
    Loeffler, M
    BLOOD, 1998, 92 (10) : 177B - 177B
  • [3] Cost-effectiveness analysis of G-CSF in elderly patients with aggressive non-Hodgkin's lymphoma (NHL) receiving CHOP
    Lyman, GH
    Cosler, LE
    VALUE IN HEALTH, 2006, 9 (03) : A107 - A107
  • [4] Rituximab-CHOP or two-weekly CHOP plus G-CSF in aggressive lymphoma of the elderly?
    Todeschini, G
    Gelio, S
    Tecchio, C
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 538 - 539
  • [5] A new strategy with CHOP-rituximab (RTX) plus GM-CSF in the salvage treatment of 33 patients with aggressive NHL.
    Olivieri, A
    Capelli, D
    Lucesole, M
    Montanari, M
    Brunori, M
    Gini, G
    Spitaleri, L
    Poloni, A
    Offidani, M
    Leoni, P
    BLOOD, 2001, 98 (11) : 245B - 245B
  • [6] Cost-effectiveness analysis of adjunct G-CSF with a novel oral combination chemotherapy regimen for the treatment of AIDS-related NHL.
    Stinson, TJ
    Freidberg, M
    Kumar, N
    Anand, P
    Ramnes, C
    Lee, E
    Waters, TM
    Remick, SC
    Bennett, CL
    BLOOD, 1998, 92 (10) : 231B - 231B
  • [7] 2-weekly chop (CHOP-14):: The new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age.
    Pfreundschuh, M
    Trümper, L
    Kloess, M
    Schmitz, N
    Schmits, R
    Glass, B
    Hasenclever, D
    Engert, A
    Rudolph, C
    Illiger, J
    Hossfeld, D
    Rübe, C
    Loeffler, M
    BLOOD, 2001, 98 (11) : 725A - 725A
  • [8] High Dose Etoposide Plus G-CSF As an Effective Mobilization Regimen in Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study
    Hyun, Shin Young
    Kim, Yu Ri
    Kim, Yun Deok
    Whang, Do Yoo
    Kim, Soo Jeong
    Cheong, June-Won
    Lee, Hong Ghi
    Yang, Deok-Hwan
    Ahn, Jae Sook
    Lee, Won-Sik
    Mo, Ryu Hon
    Do, Young-Rok
    Lee, Ho Sup
    Lee, Jae Hoon
    Oh, Sung Yong
    Suh, Cheolwon
    Yhim, Ho-Young
    Kim, Jin Seok
    BLOOD, 2012, 120 (21)
  • [9] 2-weekly vs. 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL):: Results of the completed NHL-B-2 trial of the DSHNHL.
    Pfreundschuh, M
    Truemper, L
    Kloess, M
    Schmits, R
    Schmitz, N
    Glass, B
    Engert, A
    Rudolph, C
    Mezger, D
    Hossfeld, D
    Loeffler, M
    BLOOD, 2002, 100 (11) : 774A - 774A
  • [10] Randomized trial of granulocyte-colony stimulating factor (G-CSF) added to CHOP in elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
    Doorduijn, JK
    van der Holt, B
    van der Hem, KG
    van Imhoff, GW
    Kramer, MHH
    van Oers, MHJ
    Ossenkoppele, GJ
    Schaafsma, MR
    Verdonck, LF
    Verhoef, GEG
    Steijaert, MMC
    Lowenberg, B
    Sonneveld, P
    BLOOD, 2000, 96 (11) : 133A - 133A
12345